相关临床试验
10
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1991
已完成
5
50.0%
尚未招募
1
10.0%
招募中
4
40.0%
暂无批准数据
- A Cleveland Clinic study of over 1,000 patients found that low-dose ketamine infusions led to significant improvements in pain, physical function, and sleep for 20-46% of chronic pain patients, with benefits lasting at least six months. - A comprehensive Cochrane review analyzing 67 trials with 2,309 participants found no convincing evidence that ketamine provides meaningful benefits for chronic pain management compared to placebo. - The Cochrane review highlighted safety concerns including psychotomimetic effects such as delusions, delirium, and paranoia, while the Cleveland Clinic study reported minimal side effects with rare hallucinations. - Despite widespread off-label prescribing for chronic pain conditions, researchers emphasize the urgent need for high-quality trials to establish ketamine's true clinical value in pain management.
- A comprehensive review of 301 clinical trials reveals only 10% of treatments for low back pain show evidence of effectiveness, with most providing only marginal relief compared to placebo. - For acute low back pain, NSAIDs like aspirin and ibuprofen demonstrate moderate effectiveness, while chronic back pain may respond to exercise, spinal manipulation, taping, antidepressants, and warming creams. - Researchers specifically identified ineffective treatments including exercise, steroid injections, and acetaminophen for acute pain, and antibiotics and anesthetics for chronic back pain.
- PainWaive, an interactive, home-based EEG neurofeedback system, is set to begin randomized controlled trials in 2025 for neuropathic pain management in spinal cord injury (SCI) patients. - Developed by UNSW Sydney and Neuroscience Research Australia (NeuRA), PainWaive uses a headset and tablet app to help users regulate brain activity associated with neuropathic pain. - The system provides real-time feedback through interactive games, aiming to teach users self-regulation techniques for long-term pain reduction without invasive procedures. - A pilot study has been completed, and the upcoming StoPain trial will involve 20 sessions over four weeks to assess the intervention's effectiveness.
